Adverse Events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Veriton Pharma Ltd.
Tel: + 44 (0)1932 690325.

         You are now leaving this website.

Veriton Pharma Ltd is not responsible for the information on the website to which you are linking.

CONTINUE

Healthcare Professionals    -    Administration    -    Instructions to administer Epistatus

How to
administer Epistatus
-

Instructions to administer Epistatus

Instructions to administer Epistatus

Epistatus is for oromucosal (“buccal”) use only, and must only be used in the mouth. It should be administered directly from the pre-filled buccal syringe into the patient’s buccal cavity (the space between the inner cheek and the gums):

Epistatus 10mg in 1mL oromucosal solution midazolam (as maleate) image of closed syringe case

Pull the tamper evident tab on the side of the plastic packaging case, open it and take the syringe out.

Epistatus pre-filled syringe in open case

Do not use if the solution is not clear (e.g. if it’s cloudy or white particles are present)

Epistatus pre-filled syringe with amber sheath cap partially removed

Holding the clear finger grips, unscrew the amber sheath cap in an anti-clockwise direction.

Epistatus pre-filled syringe with amber sheath cap entirely removed

Remove the amber sheath cap and dispose of it safely.

Carer's hand gently pinchng patient's cheek to allow space for syringe

Using your finger and thumb, gently pinch and pull back the patient’s cheek. Place the tip of the syringe into the back of the space between the inside cheek and the lower gum (buccal cavity).

Carer's hand slowly administering half of solution into patient's available buccal cavity

Slowly administer approximately half of the solution to the buccal cavity on one side of the mouth, and then administer the remainder slowly to the other side, by pressing the syringe plunger until it stops. If it is particularly difficult to get the syringe into one buccal cavity, then administer the whole dose over a duration of 4-5 seconds into the other buccal cavity.

Patient's face highlighting target area where Epistatus was administered

Any unused product or waste material should be disposed of safely.

Epistatus 10mg in 1mL oromucosal solution midazolam (as maleate) brand logo
10mg in 1mL Oromucosal Solution
Midazolam (as maleate)
Veriton Pharma brand logo

© 2017 Veriton Pharma Ltd. All Rights Reserved. Please read the Legal Notice for further details. Company Registration No. 03305136.

This website is produced and maintained by Veriton Pharma Ltd. and includes promotional content.

This information is intended only for the use of healthcare professionals in the United Kingdom. If you are not a healthcare professional, please click here.

Item code number EDM-1022-2019. Date of preparation: March 2019.

Prescribing information

Summary of product characteristics

Report an adverse event

Site map

Contact us

Privacy policy

Terms and conditions